相关实验视频

Updated: May 16, 2025

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

针对线粒体和ROS敏感的主链聚合物克服了癌症抗药性

Xuan Li¹, Hanchen Zhang², Zheng Cao³

¹Key Laboratory of Environmentally Friendly Chemistry and Applications of Ministry of Education, College of Chemistry, Xiangtan University, Xiangtan 411105, PR China; Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, PR China.

Journal of controlled release : official journal of the Controlled Release Society

|May 14, 2025

概括

一种基于的新型聚合物纳米颗粒,NP@PolyRu,通过向线粒体和克服耐药性,有效治疗肺癌. 它表现出显著的瘤抑制和抗瘤免疫效应,具有良好的生物相容性.

科学领域:

材料科学材料科学材料科学
纳米技术纳米技术
在瘤学瘤学.

背景情况:

基于的化疗耐药性限制了肺癌治疗的有效性.
开发新的基于金属的抗瘤剂至关重要.
复合物提供了作为替代抗癌药物的潜力.

研究的目的:

开发和评估一种新型的两聚合物PolyRu,它含有用于肺癌治疗的复合物.
研究NP@PolyRu.Ru的自我组装,瘤微环境响应性降解和抗癌机制.
在肺癌模型中评估NP@PolyRu的体内抗瘤疗效和生物相容性.

主要方法:

合成PolyRu,一种带有复合物和硫基键的两性聚合物.
在水溶液中将PolyRu自组装成纳米粒子 (NP@PolyRu).
在实验室评估NP@PolyRu在活性氧物种 (ROS) 中的降解.
在人体肺癌患者衍生异种移植模型的体内疗效研究.
评估NP@PolyRu的线粒体向,亡诱导,生物相容性和抗瘤免疫作用.

主要成果:

聚Ru自组装成纳米粒子 (NP@PolyRu),在富含ROS的瘤环境中降解.
在NP@PolyRu中的复合物向癌细胞线粒体,诱导细胞亡.
在人类肺癌异种移植模型中,NP@PolyRu显著抑制了瘤进展.
在NP@PolyRu治疗时观察到有利的生物相容性和显著的抗瘤免疫作用.

结论:

NP@PolyRu代表了一种有前途的金属聚合物治疗方法,用于克服肺癌药物耐药性.
纳米颗粒的设计使得向药物输送和瘤特异性降解成为可能.
NP@PolyRu显示出显著的治疗潜力,为基于金属的癌症治疗提供了一个新的战略.

关键词:

肺癌是一种肺癌.金属聚合物的金属聚合物.以线粒体为目标的线粒体纳米技术纳米技术克服阻力克服阻力

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...